Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
3 papers
Major depressive disorder is a serious illness. Researchers reviewed how ketamine — a drug that blocks a brain receptor called the NMDA receptor — can lift depression symptoms quickly and for a sustained time in people and in animals. They describe possible ways ketamine works: it may boost another type…
This review explains how ketamine, a drug that blocks NMDA receptors, might work for people with treatment‑resistant depression. It says one injection of ketamine can rapidly reduce depressive symptoms, including acute suicidal behavior. The paper describes steps that could explain this: ketamine may raise glutamate, trigger growth of neuron branches,…
Researchers isolated two compounds from the medicinal mushroom Hericium erinaceus—N-de phenylethyl isohericerin (NDPIH) and hericene A. In lab cultures, these compounds caused strong axon growth and more branching in hippocampal neurons even without serum. Tests showed they activate ERK1/2 signaling and do not act only through the TrkB (BDNF) receptor.…
